for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Valneva SE

VLS.PA

Latest Trade

2.62EUR

Change

0.04(+1.55%)

Volume

191,423

Today's Range

2.56

 - 

2.62

52 Week Range

2.51

 - 

3.78

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Valneva 9-month EBITDA Down At 3.0 Million Euros

Oct 31 (Reuters) - Valneva SE <VLS.PA>::VALNEVA RAISES PRODUCT SALES GUIDANCE FOLLOWING STRONG NINE-MONTH RESULTS AND RESEARCH AND DEVELOPMENT EXECUTION.VALNEVA RAISES PRODUCT SALES GUIDANCE FOLLOWING STRONG NINE-MONTH RESULTS AND RESEARCH AND DEVELOPMENT EXECUTION.2019 OUTLOOK: VALNEVA NOW PROJECTS PRODUCT SALES REVENUES OF EUR 125 MILLION TO EUR 130 MILLION REPRESENTING YEAR ON YEAR GROWTH EXCEEDING 20%.EXCLUDING THIS GSK SAA TERMINATION EFFECT, EXPECTED OVERALL REVENUES WOULD BE BETWEEN EUR 135 MILLION - EUR 140 MILLION.ALSO CONFIRMS EXPECTED EBITDA, IN LINE WITH ITS PREVIOUS GUIDANCE, OF EUR 5 MILLION TO EUR 10 MILLION IN 2019.WE FEEL CONFIDENT ABOUT OUR FULL-YEAR OUTLOOK AND RAISE OUR PRODUCT SALES GUIDANCE.PRODUCT SALES REVENUE OF EUR 86.4 MILLION IN FIRST NINE MONTHS OF 2019.STRONG CASH POSITION OF €67.4 MILLION AT THE END OF SEPTEMBER 2019.TOTAL REVENUES OF EUR 81.4 MILLION IN FIRST NINE MONTHS OF 2019.EUR 92.1 MILLION EXCLUDING NEGATIVE REVENUE IMPACT FROM TERMINATION OF GSK SAA.POSITIVE EBITDA OF EUR 3.0 MILLION IN FIRST NINE MONTHS OF 2019.NET LOSS OF EUR 2.4 MILLION IN FIRST NINE MONTHS OF 2019.Q3 CASH AND CASH EQUIVALENTS AT END-SEPT EUR 67.4 MILLION VERSUS EUR 33.0 MILLION YEAR AGO.COMPLETION OF PATIENT RECRUITMENT FOR PHASE 2 STUDIES OF ITS LYME DISEASE VACCINE CANDIDATE, VLA15.RESULTS OF THESE STUDIES, COMPRISING IMMUNOGENICITY AND SAFETY DATA, WILL SUPPORT DOSE AND VACCINATION SCHEDULE TO BE USED IN PHASE 3.

Valneva Confirms Delisting From Vienna Stock Exchange

Sept 19 (Reuters) - VALNEVA SE <VLS.PA>::VALNEVA CONFIRMS DELISTING FROM THE VIENNA STOCK EXCHANGE.VALNEVA SHARES WILL BE AUTOMATICALLY TRANSFERRED TO EURONEXT PARIS.VALNEVA’S LISTING ON EURONEXT PARIS REMAINS UNCHANGED.

Valneva Confirms Delisting From The Vienna Stock Exchange

Valneva SE <VLS.PA>::VALNEVA CONFIRMS DELISTING FROM THE VIENNA STOCK EXCHANGE.VALNEVA SE - LAST VSE TRADING DAY WILL TAKE PLACE ON DECEMBER 20.VALNEVA SE - VALNEVA'S LISTING ON EURONEXT PARIS REMAINS UNCHANGED.VALNEVA SE - SHARES WILL BE AUTOMATICALLY TRANSFERRED TO EURONEXT PARIS.

Valneva H1 Net Loss Widens To 2.4 Million Euros

Aug 1 (Reuters) - VALNEVA SE <VLS.PA>::VALNEVA REPORTS H1 2019 RESULTS MARKED BY STRONG OPERATIONAL PERFORMANCE AND MAJOR CORPORATE PROGRESS.TOTAL REVENUES OF EUR 54.5 MILLION IN H1 2019.GROSS MARGIN ON PRODUCT SALES REVENUE OF 66.1% IN H1 2019 VS 60.0% YR AGO.NET LOSS OF EUR 2.4 MILLION IN H1 2019 VS EUR 0.2 MILLION YR AGO.STRONG CASH POSITION OF EUR 69.9 MILLION AT END OF JUNE 2019.

Valneva Draws Down Further 10 Million Euros From Its Existing European Investment Bank Loan

July 16 (Reuters) - VALNEVA SE <VLS.PA>::VALNEVA ANNOUNCES DRAWDOWN OF FURTHER €10 MILLION FROM ITS EXISTING EUROPEAN INVESTMENT BANK LOAN.VALNEVA HAS NOW DRAWN DOWN EUR 20 MILLION(1) OF EUR 25 MILLION FACILITY..COMPANY DOES NOT INTEND TO DRAW DOWN REMAINING EUR 5 MILLION OF FACILITY..VALNEVA PLANS TO USE FUNDS TO ADVANCE ITS RESEARCH AND DEVELOPMENT PROGRAMS.EACH CREDIT TRANCHE IS REPAYABLE AT END OF A FIVE-YEAR PERIOD COMMENCING FROM DRAWDOWN DATE.

Valneva Submits Delisting Application To Vienna Stock Exchange

July 2 (Reuters) - VALNEVA SE <VLS.PA>::REG-VALNEVA SUBMITS DELISTING APPLICATION TO THE VIENNA STOCK EXCHANGE.DELISTING SHALL BE EFFECTIVE BY END OF 2019.LISTING ON EURONEXT PARIS REMAINS UNCHANGED.VSE WILL NOW HAVE TEN WEEKS TO DECIDE ON APPLICATION AND TIMELINE OF DELISTING.

Valneva Initiates Second Phase 2 Study For VLA15

July 1 (Reuters) - Valneva SE <VLS.PA>::REG-VALNEVA INITIATES SECOND PHASE 2 STUDY FOR ITS LYME DISEASE VACCINE CANDIDATE VLA15.PHASE 2 DURATION IS EXPECTED TO BE APPROXIMATELY TWO YEARS WITH INITIAL DATA (PRIMARY ENDPOINT) EXPECTED MID-2020.OVERALL PHASE 2 OBJECTIVES FOR VLA15 ARE TO DETERMINE OPTIMAL DOSAGE LEVEL AND VACCINATION SCHEDULE FOR USE IN PHASE 3 PIVOTAL FIELD EFFICACY STUDIES, BASED ON IMMUNOGENICITY AND SAFETY DATA.

Valneva Reports Successful Outcome of Phase 2 Run-In for VLA15

June 12 (Reuters) - VALNEVA SE <VLS.PA>::ANNOUNCED PROGRESS OF ITS ONGOING PHASE 2 STUDY FOR ITS LEADING, UNIQUE LYME DISEASE VACCINE CANDIDATE, VLA15.BASED ON DSMB CLEARANCE, TWO LEAD DOSAGE LEVELS HAVE BEEN SELECTED FOR ONGOING PHASE 2 CLINICAL DEVELOPMENT.PRELIMINARY PHASE 2 RESULTS (PRIMARY ENDPOINT) ARE ANTICIPATED - AS PREVIOUSLY ANNOUNCED - MID-2020.VACCINE CANDIDATE HAS A FAVORABLE SAFETY PROFILE AND WAS IMMUNOGENIC IN ALL DOSES AND FORMULATIONS TESTED.AS PART OF VLA15-201 RUN-IN PHASE, 120 SUBJECTS RECEIVED ONE OF THREE ALUM ADJUVANTED DOSE LEVELS OF VLA15 (90ΜG, HIGH DOSE FROM PHASE 1, 135ΜG OR 180ΜG) OR PLACEBO..DSMB HAS REVIEWED SAFETY DATA FROM THOSE SUBJECTS AND HAS CLEARED 135ΜG AND 180ΜG DOSAGE LEVELS FOR FURTHER INVESTIGATION IN MAIN STUDY PHASE..COMPANY EXPECTS THIS STUDY TO COMMENCE IN Q3 OF THIS YEAR.STARTED PREPARATIONS TO INITIATE A FURTHER PHASE 2 STUDY (VLA15-202) TO EVALUATE AN ALTERNATIVE IMMUNIZATION SCHEDULE.

Valneva Reports Further Positive Results For Its Chikungunya Vaccine Candidate

May 22 (Reuters) - VALNEVA SE <VLS.PA>::VALNEVA REPORTS FURTHER POSITIVE RESULTS FOR ITS CHIKUNGUNYA VACCINE CANDIDATE.VLA1553 WAS GENERALLY SAFE IN ALL DOSE GROUPS.EXCELLENT IMMUNOGENICITY PROFILE IN ALL DOSE GROUPS AFTER A SINGLE VACCINATION * 100% SEROCONVERSION(1) ACHIEVED AT DAY 14 AFTER A SINGLE VACCINATION IN ALL DOSE GROUPS.TO LICENSURE FOR ITS FDA FAST TRACKED CANDIDATE VLA1553 AT ITS PLANNED RESEARCH AND DEVELOPMENT INVESTOR DAY, JULY 9.SUSTAINED AT 100% AFTER SIX MONTHS.

Valneva Q1 Net Profit Grows To 4.9 Million Euros

May 2 (Reuters) - VALNEVA SE <VLS.PA>::Q1 NET PROFIT EUR 4.9 MILLION VERSUS EUR 1.5 MILLION YEAR AGO.EBITDA OF EUR 8.2 MILLION IN Q1 2019.Q1 TOTAL REVENUE EUR 34.9 MILLION VERSUS 32.1 MILLION YEAR AGO.CASH AT END OF PERIOD EUR 68.1 MILLION VERSUS EUR 36.2 MILLION YEAR AGO.Q1 EBITDA EUR 8.2 MILLION VERSUS EUR 4.9 MILLION YEAR AGO.VALNEVA EXPECTS DUKORAL REVENUES TO GROW BY UP TO 5% (CER) IN 2019.POSITIVE PHASE 1 INTERIM RESULTS FOR CHIKUNGUNYA VACCINE CANDIDATE, VLA1553.VALNEVA PROJECTS THAT REVENUES FROM IXIARO(®)/JESPECT(®) SALES WILL GROW AT A MINIMUM OF 15% (CER) IN 2019.EXPECTS GROWTH IN 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up